



I hereby certify that this paper or fee is being deposited with the United States Postal Service with sufficient postage as first class mail under 37 C.F.R. 1.8 on the date indicated below and is addressed to: MAILSTOP: MISSING PARTS, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: April 15, 2004

Selena Whitaker-Paquiet

Attorney Docket No. 13311.1001U PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of Chris JOLLY

Group Art Unit: 1741

Application No. :

10/672,764

Filed

September 26, 2003

For

IMMUNOGLOBULIN COMPOSITIONS AND METHODS

## **INFORMATION DISCLOSURE STATEMENT**

MAIL STOP: MISSING PARTS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir or Madam,

The attached form PTO/SB/08 (substitute for form 1449A/PTO) identifies 1 published U.S. patent application, 4 published International patent applications, 1 published foreign patent application and 2 literature references. A copy of each of the cited references is enclosed herewith for the Examiner's convenience.

The documents listed on the accompanying form PTO/SB/08 are cited in compliance with the provisions of 37 C.F.R §§ 1.56, 1.97 and 1.98, as amended. Applicant does not concede that the references are "prior art" under 35 U.S.C. §102 or §103, and specifically reserves the right to antedate such materials, as by a showing under 37 C.F.R. § 1.131 or otherwise.

These references were cited in an International Search Report, a copy of which is enclosed, for a corresponding PCT application and prior to receipt of any substantive Office Action. No fee is therefore required for filing this Information Disclosure Statement.

Respectfully submitted,

Gary M. Myles

Registration No. 46,209

Date: April 15, 2004

SPECKMAN LAW GROUP

20601

PTO/SB/08 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known for form 1449A/PTO Application Number 10/672,764 ORMATION DISCLOSURE Filing Date September 26, 2003 STATEMENT BY APPLICANT First Named Inventor **Chris JOLLY** (use as many sheets as necessary) Art Unit 1741 Examiner Name 1 of Attorney Docket Number 13311.1001U Sheet

	U.S. PATENT DOCMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant		
Initials*	No.1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear		
	1	US-2002/0187131 A1	Dec. 12, 2002	Hawiger, et al.			
	2	US-					
	3	US-					
	4	us-					
	5	us-					
	6	us-					
	7	, us-					
	8	US-					
	9	US-					
	10	US-					

		FOREIG	GN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
		Country code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				T <sup>6</sup>
	1	WO 01/09186 A2	Feb. 8, 2001	Medarex, Inc.,		
	2	WO 00/00156	Jan. 6, 2000	Trustees of Dartmouth College		
	3	WO 99/36507	Jul. 22, 1999	Genetrix LLC		
	4	WO 97/45449	Dec. 4, 1997	Hart, Derek et al.		
	5	EP 1 046 651 A1	Oct. 25, 2000	Koninklijke Universiteit Nijmegen		

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²			
1	HAWIGER, Daniel et al., "Dendritic Cells Induce Peripheral T. Cell Unresponsiveness Under Steady State Conditions In Vivo," Journal of Experimental Medicine, Vol. 194, No. 6, pp. 769-779 (September 17, 2001)				
2	BONIFAZ, Laura et al., "Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8'T Cell Tolerance," <i>Journal of Experimental Medicine</i> , Vol. 196, No. 12, pp. 1627-1638 (December 16, 2002)				
3					
	No. <sup>1</sup> 1 2	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published  HAWIGER, Daniel et al., "Dendritic Cells Induce Peripheral T. Cell Unresponsiveness Under Steady State Conditions In Vivo," Journal of Experimental Medicine, Vol. 194, No. 6, pp. 769-779 (September 17, 2001)  BONIFAZ, Laura et al., "Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8'T Cell Tolerance," Journal of Experimental Medicine, Vol. 196, No. 12, pp. 1627-1638 (December 16, 2002)			

Examiner	Date	7.63
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.